Abcentra: Better Solutions, Better Results

Some of the most chronic and difficult-to-treat conditions in the United States are caused by inflammation — an immune response by the body to a stressor. Conditions like plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis affect millions of patients each year, however, these life-threatening and fatal diseases lack effective treatment options. Without a suitable treatment option, doctors and clinicians often leverage therapies that treat the symptoms of the disease yet don’t address the underlying cause.

Therapies that target and treat inflammation are important tools in the fight against inflammatory diseases. These may help create a better quality of life for patients, however, traditional immunomodulating biological drugs (IBDs) are limited in reach and may have severe side effects like infections, cancer and death. We’ve set out to create a better treatment option.

What we are doing

We are developing anti-inflammatory monoclonal antibodies with novel mechanisms of action. We believe that by directly targeting the root cause of inflammation, we can  alleviate symptoms and treat underlying disease, creating a fuller life for patients.

How we are doing it

We target oxidized low density lipoprotein (oxLDL), which is implicated in common, chronic conditions caused by inflammation such as cardiovascular disease, rheumatological diseases and cancer. By targeting oxLDL, we can create new, safer and more effective treatment options to patients with inflammatory diseases.

Our lead candidate

Our lead candidate, orticumab, is the first and only fully-human monoclonal antibody of its kind targeting oxLDL, which we are developing to treat patients  with plaque psoriasis and accelerated atherosclerosis. With three clinical trials completed to date, our candidate has demonstrated an excellent safety profile and has shown evidence of activity in humans.

Read more about our lead candidate here, then view our pipeline to learn more about the other treatment options currently in development.